Search Results for "Hydrocodone Bitartrate 7 5 Mg"

22:31 EST 1st March 2015 | BioPortfolio

Matching Channels

None

Matching News

Teva Pharma: FDA Accepts For Review NDA For Hydrocodone Bitartrate ER Tablets

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced the U.S. FDA has accepted for review the New Drug Application (NDA) for the company's hydrocodone bitartrate extended-r...

Vycavert hydrocodone bitartrate/acetaminophen regulatory update

Mallinckrodt Pharmaceuticals Releases Human Abuse Liability (HAL) Data for Investigational MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination

HAL study compared subjective effects of drug liking, drug high and good drug effects between MNK-155 and an immediate-release hydrocodone bitartrate/acetaminophen formulation in ...

FDA Approves Hysingla ER - Extended-Release Hydrocodone with Abuse-Deterrent Properties

November 20, 2014 -- The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, ...

Abuse-Resistant Prescription Painkiller Approved

THURSDAY, Nov. 20, 2014 -- The U.S. Food and Drug Administration has approved Hysingla ER (hydrocodone bitartrate), an abuse-resistant, extended release form of the painkiller hydrocodone (best known ...

Mallinckrodt Pharmaceutical’s MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial

MNK-155 (hydrocodone bitartrate/acetaminophen) demonstrated significantly greater pain reduction than placebo following bunion surgery Mallinckrodt (NYSE: MNK) t...

Purdue Pharma's harder-to-abuse painkiller wins FDA approval

Purdue Pharma has won the FDA's approval to market Hysingla ER, or hydrocodone bitartrate, a once-daily, long-acting narcotic -More- 

FDA approves hydrocodone product with abuse-deterrent properties

The FDA has approved Purdue Pharma’s Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid...

Matching PubMed Articles

Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.

(1) To quantify hydrocodone (HC) and hydromorphone (HM) metabolite pharmacokinetics with pharmacogenetics in CYP2D6 ultra-rapid (UM), extensive (EM) and poor (PM) metabolizer phenotypes. (2) To develo...

Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.

Infantile neuronal ceroid lipofuscinosis is a devastating neurodegenerative lysosomal storage disease caused by mutations in the gene (CLN1 or PPT1) encoding palmitoyl-protein thioesterase-1 (PPT1). W...

Chemisorptive enantioselectivity of chiral epoxides on tartaric-acid modified Pd(111): three-point bonding.

The chemisorption of two chiral molecules, propylene oxide and glycidol, is studied on tartaric-acid modified Pd(111) surfaces by using temperature-programmed desorption to measure adsorbate coverage....

Rescheduling of Combination Hydrocodone Products: Problems for Long-Term Care Practitioners.

The Drug Enforcement Administration recently announced the final rule to reschedule hydrocodone combinations from schedule III of the Controlled Substances Act to the more restrictive schedule II cate...

DEA Tightens Restrictions on Hydrocodone Combination Products.

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement